Theravance Biopharma, Inc.

NasdaqGM:TBPH Stock Report

Market Cap: US$434.0m

Theravance Biopharma Management

Management criteria checks 1/4

Theravance Biopharma's CEO is Rick Winningham, appointed in Jun 2014, has a tenure of 9.75 years. total yearly compensation is $6.27M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 3.42% of the company’s shares, worth $14.84M. The average tenure of the management team and the board of directors is 1.8 years and 7.3 years respectively.

Key information

Rick Winningham

Chief executive officer

US$6.3m

Total compensation

CEO salary percentage16.7%
CEO tenure9.8yrs
CEO ownership3.4%
Management average tenure1.8yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

Theravance Biopharma EPS misses by $0.16, misses on revenue

May 04

Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Apr 21
Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Mar 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Mar 08
Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

CEO Compensation Analysis

How has Rick Winningham's remuneration changed compared to Theravance Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$55m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$6mUS$1m

-US$93m

Sep 30 2022n/an/a

-US$136m

Jun 30 2022n/an/a

-US$196m

Mar 31 2022n/an/a

-US$226m

Dec 31 2021US$4mUS$1m

-US$265m

Sep 30 2021n/an/a

-US$266m

Jun 30 2021n/an/a

-US$264m

Mar 31 2021n/an/a

-US$275m

Dec 31 2020US$7mUS$1m

-US$295m

Sep 30 2020n/an/a

-US$285m

Jun 30 2020n/an/a

-US$270m

Mar 31 2020n/an/a

-US$247m

Dec 31 2019US$6mUS$984k

-US$236m

Sep 30 2019n/an/a

-US$221m

Jun 30 2019n/an/a

-US$222m

Mar 31 2019n/an/a

-US$223m

Dec 31 2018US$3mUS$957k

-US$216m

Sep 30 2018n/an/a

-US$252m

Jun 30 2018n/an/a

-US$260m

Mar 31 2018n/an/a

-US$285m

Dec 31 2017US$2mUS$933k

-US$285m

Compensation vs Market: Rick's total compensation ($USD6.27M) is above average for companies of similar size in the US market ($USD2.15M).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.


CEO

Rick Winningham (63 yo)

9.8yrs

Tenure

US$6,272,907

Compensation

Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022 . He has been Lead Independent Director and Director of Jazz Pharmaceuticals Public Limited Compa...


Leadership Team

NamePositionTenureCompensationOwnership
Rick Winningham
Chairman & CEO9.8yrsUS$6.27m3.42%
$ 14.8m
Rhonda Farnum
Chief Business Officer and Senior VP of Commercial & Medical Affairs2.3yrsUS$942.81k0.65%
$ 2.8m
Aziz Sawaf
Senior VP & CFO1.2yrsno data0.50%
$ 2.2m
Stuart Knight
VP of IT&I & Chief Information Officerno datano datano data
Gail Cohen
Vice President of Corporate Communications & Investor Relationsno datano datano data
Brett Grimaud
Senior VP1.8yrsno data0.54%
$ 2.3m
Stacy Pryce
Senior VP & Chief Strategy Officer1.5yrsno datano data
Aine Miller
SVP of Dev.no datano data0.28%
$ 1.2m

1.8yrs

Average Tenure

53.5yo

Average Age

Experienced Management: TBPH's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Rick Winningham
Chairman & CEO10.7yrsUS$6.27m3.42%
$ 14.8m
Eran Broshy
Independent Director9.8yrsUS$223.12k0.13%
$ 548.6k
Burton Malkiel
Independent Director10.4yrsUS$235.62k0.24%
$ 1.0m
Deepika Pakianathan
Independent Director3.7yrsUS$224.94k0.077%
$ 332.3k
Dean Mitchell
Lead Independent Director9.8yrsUS$218.12k0.15%
$ 630.9k
James Kelly
Independent Directorless than a yearno datano data
Donal O'Connor
Independent Director8.4yrsUS$215.62k0.11%
$ 477.7k
Susannah Gray
Independent Director1.1yrsno data0.043%
$ 188.8k
Laurie Smaldone Alsup
Independent Director6.1yrsUS$220.62k0.11%
$ 484.7k
Jeremy Grant
Independent Directorless than a yearno data0.024%
$ 106.0k

7.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: TBPH's board of directors are considered experienced (7.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.